- Home
- FOLD vs APGE Comparison
FOLD vs APGE Comparison
Compare FOLD & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- APGE
- Stock Information
- Founded
- FOLD 2002
- APGE 2022
- Country
- FOLD United States
- APGE United States
- Employees
- FOLD N/A
- APGE N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FOLD Health Care
- APGE Health Care
- Exchange
- FOLD Nasdaq
- APGE Nasdaq
- Market Cap
- FOLD 2.5B
- APGE 2.4B
- IPO Year
- FOLD 2007
- APGE 2023
- Fundamental
- Price
- FOLD $9.41
- APGE $63.13
- Analyst Decision
- FOLD Buy
- APGE Strong Buy
- Analyst Count
- FOLD 7
- APGE 9
- Target Price
- FOLD $30.29
- APGE $97.33
- AVG Volume (30 Days)
- FOLD 5.0M
- APGE 717.2K
- Earning Date
- FOLD 11-04-2025
- APGE 11-10-2025
- Dividend Yield
- FOLD N/A
- APGE N/A
- EPS Growth
- FOLD N/A
- APGE N/A
- EPS
- FOLD N/A
- APGE N/A
- Revenue
- FOLD $598,704,000.00
- APGE N/A
- Revenue This Year
- FOLD $21.12
- APGE N/A
- Revenue Next Year
- FOLD $21.23
- APGE N/A
- P/E Ratio
- FOLD N/A
- APGE N/A
- Revenue Growth
- FOLD 21.28
- APGE N/A
- 52 Week Low
- FOLD $5.51
- APGE $26.20
- 52 Week High
- FOLD $10.83
- APGE $64.87
- Technical
- Relative Strength Index (RSI)
- FOLD 67.64
- APGE 74.88
- Support Level
- FOLD $8.69
- APGE $52.34
- Resistance Level
- FOLD $9.64
- APGE $57.31
- Average True Range (ATR)
- FOLD 0.38
- APGE 3.00
- MACD
- FOLD 0.03
- APGE 0.20
- Stochastic Oscillator
- FOLD 82.68
- APGE 86.68
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.